Arvinas Presents Promising Preclinical Data for BCL6 Degrader ARV-393 in Lymphoma Treatment

Arvinas Inc. (NASDAQ:ARVN) is one of the best low priced pharma stocks to buy now. Earlier on June 13, Arvinas presented encouraging preclinical data for its investigational PROteolysis TArgeting Chimera/PROTAC B-cell lymphoma 6 protein (BCL6) degrader, called ARV-393, at the European Hematology Association/EHA 2025 Congress in Milan, Italy. BCL6 drives B-cell lymphomas.

The studies highlighted ARV-393’s single-agent activity. In a patient-derived xenograft/PDX model of nodal T-follicular helper cell lymphoma, angioimmunoblastic-type (nTFHL-AI, also known as AITL), derived from a patient who relapsed post-chemotherapy, ARV-393 substantially reduced tumor burden in the peripheral blood, bone marrow, and spleen.

Arvinas Presents Promising Preclinical Data for BCL6 Degrader ARV-393 in Lymphoma Treatment

A biopharma executive in a meeting room discussing the clinical-stage of a new therapy.

This represents a potential first for preclinical evidence of anti-tumor activity by an efficacious BCL6-targeted small-molecule degrader in a human nTFHL-AI model. Furthermore, ARV-393 monotherapy achieved robust tumor growth inhibition/TGI of at least 95% in two PDX models of transformed follicular lymphoma/tFL.

Arvinas Inc. (NASDAQ:ARVN) is a clinical-stage biotechnology company that discovers, develops, and commercializes therapies to degrade disease-causing proteins.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.